Rennova Health, Inc. (NASDAQ:RNVA) registered a -1.41% decrease, still its new closing price is 14.38% up from the company’s 1 year high of 1.16.It posted -15.76% losses in previous 5 sessions and is now the subject of 22 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 1 sells versus 8 buy or better ratings. The 0 stock analysts following this company have an average price target at $18.50, with individual PT in the $18.50-$18.50 range. The shares moved at $0.07, implying that brokerage firms see shares losing about -93.14% in twelve months time.
Rennova Health, Inc. (RNVA) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a -15.66% fall year to date. A Director at Rennova Health, Inc. (RNVA) acquired shares in a transaction closed on Thursday July 14, 2016. Diamantis Christopher Eric bought 333,333 shares in the company at $0.44 each and collected $146,001 in proceeds. Diamantis Christopher Eric now owns 681,526 shares in the company after this transaction. A Director in the company, Goldberg Michael Louis, disclosed a transaction on Thursday July 14, 2016 that ended up paying $1 from the purchase of 2,500 shares at $0.28 per share.
Rennova Health, Inc. (NASDAQ:RNVA) Upcoming Results on Tap
Rennova Health, Inc. will next provide financial results for the September 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.20 in that period. Sales during the quarter are predicted to arrive at $0.
Rennova Health, Inc. (RNVA) Brokerage Update
Over the last six months and over the last three months, the shares of Rennova Health, Inc. (RNVA), have changed -73.08% and -53.33%, respectively.